DAY 1 - November 6, 2017
1:00 p.m.-3:00 p.m.

Educational Session 1: Genome Editing and its Clinical Application

Computational and experimental development for CRISPR screens
X. Shirley Liu, Dana-Farber Cancer Institute, Boston, MA, USA

Domain-focused CRISPR screening
Christopher Vakoc, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

High-throughput functional genomics: Coding, non-coding and beyond
Wensheng Wei, School of Life Sciences, Peking University, Beijing, China

3:00 p.m.-3:15 p.m. Tea Break
3:15 p.m.-6:00 p.m.

Welcome and Keynote Address:  

Nancy E. Davidson, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Tumor suppressor and tumor maintenance genes
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, USA

New insights into the resistance of targeted therapy in cancer 

Hongyang Wang, Eastern Hepatobiliary Institute, Shanghai, China

6:00 p.m.-7:15 p.m.

Session 1: Tumor Evolution

Intratumoral heterogeneity and clonal selection of breast cancer
Zhi-ming Shao, Fudan University Shanghai Cancer Center, Shanghai, China

Clonal cooperation in breast cancer
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA, USA

7:30 p.m.-9:30 p.m.

Opening Reception

DAY 2 - November 7, 2017
8:30 a.m.-10:30 a.m.

Session 2: Cancer Genomics

Decipher inter and intratumoral heterogeneity to facilitate cancer precision medicine
Kui Wu, BGI, Shenzhen, China

Cancer evolution as a therapeutic target
Alberto Bardelli, University of Turin, Candiolo, Italy

Cancer evolution at single cell resolution
Sohrab Shah, BC Cancer Agency Vancouver Center, Vancouver, BC, Canada

10:30 a.m.-11:00 a.m. Tea Break with Light Refreshments
11:00 a.m.-1:00 p.m.

Session 3: Prevention

Genetic susceptibility of lung cancer and its potential application in precision prevention
Hongbing Shen,Nanjing Medical University, Nanjing, China

Notes from the field: Cancer prevention in rural China
Thomas W. Kensler, University of Pittsburgh, Pittsburgh, PA, USA

Aspirin and cancer: The promise of precision chemoprevention
Andrew T. Chan, Massachusetts General Hospital, Boston, MA, USA

1:00 p.m.-3:30 p.m.

Poster Session A with Lunch

Tumor Biology
Clinical Research
Clinical Trials
Experimental and Molecular Therapeutics
Prevention Research

3:30 p.m.-5:30 p.m.

Session 4: Metabolism

MYC and metabolic vulnerabilities of cancer
Chi Van Dang, Ludwig Institute for Cancer Research, New York, NY and The Wistar Institute, Philadelphia, PA, USA

Metabolic regulation of mitochondrial and lipid activity in renal cell cancer
Amato J. Giaccia, Stanford University, Stanford, CA, USA

Regulation of DNA Synthesis by APC/CCDH1
Shimin Zhao, Fudan University School of Life Sciences, Shanghai, China

DAY 3 - November 8, 2017
8:00 a.m.-8:30 a.m.

Special Session: PreCancer Atlas

PreCancer Atlas: A window to comprehensive profiles of precancer lesions
Sudhir Srivastava, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

8:30 a.m.-10:30 a.m.

Session 5: TME and Inflammation
Functional heterogeneity of the triple-negative breast cancer immune microenvironment
Morag Park, McGill University Goodman Cancer Center, QC, Canada

Systemic and microenvironmental determinants of cancer progression and metastasis
Sandra S. McAllister, Brigham and Women’s Hospital, Boston, MA, USA

Modifying tumor microenvironment and immunity through tumor vessel normalization
Gou Young Koh, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea

10:30 a.m.-11:00 a.m. Tea Break with Light Refreshments
11:00 a.m.-1:00 p.m.

Session 6: Immunology

Anti-angiogenic conditioning of the tumor immune microenvironment
Michele De Palma, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland

Innate immunity, inflammation and cancer: From bench to bedside
Alberto Mantovani, Humanitas University, Rozzano, Italy 

Cancer immunotherapy targeting Treg cells
Shimon Sakaguchi, Osaka University, Osaka, Japan

1:00 p.m.-3:30 p.m.

Poster Session B with Lunch

Molecular and Cellular Biology, Genetics
Bioinformatics and Systems Biology
Tumor Biology
Cancer Chemistry
Experimental and Molecular Therapeutics

3:30 p.m.-5:30 p.m.

Session 7: Epigenetics

Targeting aberrant gene silencing in cancer
Jean-Pierre J. Issa, Fox Chase Cancer Center, Philadelphia, PA, USA

HDAC inhibitors in solid tumors: Opportunities and challenges
Meiyu Geng, Chinese Academy of Sciences, Shanghai, China

Epigenetic drivers, passengers, and innocent bystanders
James G. Herman, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

6:00 p.m.-7:30 p.m.

Professional Advancement Session: Facilitating Clinician-Researcher Crosstalk to Improve Patient Care
Zhi-ming Shao, Fudan University Shanghai Cancer Center, Shanghai, China

Jennifer Rubin Grandis, UCSF, San Francisco, CA, USA

Thomas W. Kensler, University of Pittsburgh, Pittsburgh, PA, USA

DAY 4 - November 9, 2017
8:30 a.m.-10:30 a.m. 

Educational Session 2: Clinical Trial Design

Precision medicine lessons from window-of-opportunity trials
Jennifer Rubin Grandis, UCSF, San Francisco, CA, USA

Precision medicine clinical trial designs in the U.S.
Edward Chu, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

Lessons from biomarker driven clinical trials
Yi-Long Wu, Guangdong Lung Cancer Institute, Guangzhou, China

10:30 a.m.-11:00 a.m. Tea Break with Light Refreshments
11:00 a.m.-1:00 p.m.

Session 8: Precision Medicine

Digital pathology, liquid biopsy and the future of precision oncology
Mark S. Boguski, Inspirata, Inc., Tampa, FL, USA

Cancer and precision medicine: A community-research perspective
Carol R. Horowitz, Mount Sinai School of Medicine, New York, NY, USA

Single-cell triple omics sequencing reveals genomic, epigenomic, and transcriptomic heterogeneity in human hepatocellular carcinomas and colorectal cancers
Fuchou Tang, Peking University, Beijing, China

1:00 p.m.-1:15 p.m.

Closing Remarks

1:15 a.m.-3:00 p.m.

AACR Chemistry in Cancer Research Working Group (CICR) Town Hall and Luncheon

The AACR Chemistry in Cancer Research Working Group (CICR) cordially invites you to be its guest at the CICR Town Hall and Luncheon Come learn about this important international chemistry-focused working group as well as recent cancer drug discovery efforts within China and internationally, with presentations by Drs. Charles Z. Ding (WuXi AppTec) and John (Yuan) Wang (Eisai Inc.). This free event will also provide the opportunity to network with your colleagues and be updated on research developments!